Compare DCBO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | BWAY |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.3M | 578.5M |
| IPO Year | 2020 | 2011 |
| Metric | DCBO | BWAY |
|---|---|---|
| Price | $24.85 | $14.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $32.00 | $13.25 |
| AVG Volume (30 Days) | 71.0K | ★ 108.7K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.89 | $309.69 |
| Revenue Next Year | $11.44 | $26.21 |
| P/E Ratio | ★ $22.04 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $11.77 |
| 52 Week High | $30.80 | $26.63 |
| Indicator | DCBO | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 65.48 | 44.67 |
| Support Level | $16.37 | $14.08 |
| Resistance Level | N/A | $14.85 |
| Average True Range (ATR) | 0.78 | 0.53 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 74.89 | 19.25 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.